Screener
Beam Therapeutics BEAM Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $12,286 | $10,231 |
| Accrued expenses and other current liabilities | 39,291 | 55,267 |
| Current portion of derivative liabilities | 5,200 | 7,700 |
| Current portion of deferred revenue | 304 | 6,659 |
| Current portion of lease liability | 14,781 | 14,364 |
| Current portion of contingent consideration liabilities | 2,703 | 2,714 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's accrued expenses?
- Beam Therapeutics (BEAM) reported accrued expenses of $39.29M in Q1 2026.
- How has Beam Therapeutics's accrued expenses changed year-over-year?
- Beam Therapeutics's accrued expenses increased by 30.0% year-over-year, from $30.23M to $39.29M.
- What is the long-term trend for Beam Therapeutics's accrued expenses?
- Over 3 years (2022 to 2025), Beam Therapeutics's accrued expenses has grown at a 4.8% compound annual growth rate (CAGR), from $48.06M to $55.27M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Beam Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude